GLPwatch
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity.
Ther Adv Chronic Dis · 2016
Last updated 2026-08-29Liraglutide is a GLP-1 drug studied for weight loss in people with obesity. Clinical trials show it helps reduce body weight, though the exact amount isn’t specified in the abstract. It is compared to other weight-loss drugs and to bariatric surgery, which currently provides the most significant and long-lasting weight loss.
AI summary of the abstract below.
| Journal | Ther Adv Chronic Dis, 2016 |
|---|---|
| Citations | 42 |
| Relative citation ratio | 1.60 |
| NIH percentile | 66 |
| Molecules | liraglutide |
Abstract
There is a global obesity epidemic that will continue to be a financial burden on healthcare systems around the world. Tackling obesity through diet and exercise should always be the first intervention, but this has not proved to be effective for a large number of patients. Pharmacotherapeutic options have been limited and many previously available drugs have been withdrawn due to safety concerns. Currently, only bariatric surgery has the capability to induce both substantial and durable weight loss. This article briefly reviews the history of pharmacotherapy for obesity before focusing on the clinical trial evidence for the use of the GLP-1 agonist liraglutide as a weight loss agent and comparing its efficacy with other emerging drug therapies for obesity.
Verbatim abstract via PubMed 26977279 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.